Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Pipeline Review, H2 2016

  • ID: 3837862
  • Report
  • 31 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Pfizer Inc.
  • Proteome Sciences Plc
  • MORE
Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Pipeline Review, H2 2016

Summary

‘Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Pipeline Review, H2 2016’, provides in depth analysis on Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) targeted pipeline therapeutics.

The report provides comprehensive information on the Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26)
- The report reviews Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) targeted therapeutics and enlists all their major and minor projects
- The report assesses Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Pfizer Inc.
  • Proteome Sciences Plc
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) Overview

Therapeutics Development

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Products under Development by Stage of Development

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Products under Development by Therapy Area

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Products under Development by Indication

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Pipeline Products Glance

Early Stage Products

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Products under Development by Companies

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Products under Development by Universities/Institutes

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Companies Involved in Therapeutics Development

Pfizer Inc.

Proteome Sciences Plc

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Drug Profiles

P-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-5006739 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PS-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PS-278 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PST-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-3029 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Dormant Projects

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Featured News & Press Releases

Sep 26, 2014: Proteome Sciences Announces Excellent Toxicity Results For PS110 In Alzheimer's Disease

Sep 26, 2014: Proteome Sciences Announces Excellent Toxicity Results For PS278-05 In Alzheimer's Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Pfizer Inc., H2 2016

Pipeline by Proteome Sciences Plc, H2 2016

Dormant Projects, H2 2016 27List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Pfizer Inc.
  • Proteome Sciences Plc
  • MORE
Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Casein Kinase I Isoform Delta – Pipeline Review, H2 2016, outlays comprehensive information on the Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) Casein kinase I isoform delta (CK1D) is a member of the casein kinase 1 family of serine/threonine specific kinases. It is involved in the regulation of apoptosis, circadian rhythm, microtubule dynamics, chromosome segregation and p53-mediated effects on growth. It controls PER1 and PER2 nuclear transport and degradation. DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation of ESR1 and AIB1/NCOA3 stimulates their activity and co-activation. The molecules developed by Companies in Preclinical and Discovery stages are 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Pfizer Inc.
Proteome Sciences Plc
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll